注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Cyclerion Therapeutics Inc是一家臨床階段的生物製藥公司。該公司的主要資產CY6463是一種中樞神經系統(CNS)滲透劑、可溶性鳥苷酸環化酶(sGC)刺激劑,正在臨床開發中,用於治療阿爾茨海默病伴血管病變(ADv)、精神分裂症相關認知障礙(CIAS)、線粒體腦肌病、乳酸酸中毒和中風樣發作(MELA)。CY6463是一種口服給藥的CNS滲透劑sGC刺激器,正被開發為嚴重CNS疾病的症狀和疾病調節療法。其CNS資產CY3018是一種與CY6463相比具有CSF至血漿暴露的差异化CNS滲透劑sGC刺激器。CY3018專注於sGC刺激治療中樞神經系統疾病。 其非CNS資產包括Praliciguat和Olinciguat。Praliciguat是一種口服、每天一次的全身性sGC刺激器。Olinciguat是一種口服,每天一次的血管sGC刺激器。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Errol B. De Souza | 70 | 2021 | Independent Chairman |
Peter M. Hecht | 59 | 2019 | Director |
Mark G. Currie | 68 | 2019 | Chair of Scientific Advisory Board |
Terrance G. McGuire | 67 | 2019 | Independent Director |
Robert C. Malenka | - | 2021 | Member of Scientific Advisory Board |
Marni Joy Falk | - | 2021 | Member of Scientific Advisory Board |
David H. Salat | - | 2021 | Member of Clinical Advisory Board |
Daniela Salvemini | - | 2021 | Member of Scientific Advisory Board |
Andrew E. Budson | - | 2021 | Member of Clinical Advisory Board |
Claudio Babiloni | - | 2021 | Member of Scientific Advisory Board |
M Brandon Westover | - | 2021 | Member of Clinical Advisory Board |
Harald H. H. W. Schmidt | - | 2021 | Member of Scientific Advisory Board |
Steven E. Hyman | 72 | 2022 | Independent Director |
Eric Smith | - | 2021 | Member of Clinical Advisory Board |
Dina Katabi | - | 2023 | Director |
Michael J. Higgins | 62 | 2023 | Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核